Stent thrombosis incidence in drug eluting stents
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Cardiology Network |
 Discuss Stent thrombosis incidence in drug eluting stents further in the WikiDoc Cardiology Network |
| Adult Congenital |
|---|
| Biomarkers |
| Cardiac Rehabilitation |
| Congestive Heart Failure |
| CT Angiography |
| Echocardiography |
| Electrophysiology |
| Cardiology General |
| Genetics |
| Health Economics |
| Hypertension |
| Interventional Cardiology |
| MRI |
| Nuclear Cardiology |
| Peripheral Arterial Disease |
| Prevention |
| Public Policy |
| Pulmonary Embolism |
| Stable Angina |
| Valvular Heart Disease |
| Vascular Medicine |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overall incidence from multiple trials is in the range of 0.5-2%. How ever there is wide variation of the incidence depending on the multiple variables which influence its occurrence.
In a study of 3548 registry patients who received a DES, the cumulative incidence of definite, probable or possible ST was 1.8 %. The incidence for definite ST was 0.65% over a 15 month period ref1.
In a study of 1911 patients with DES and a follow up to a median 19.4 months , the overall incidence of ST was 0.8 % ref2.
In a study of 1731 patients undergoing SES implantation the cumulative one year ST rate was 1.7%. This number was 3.2% for diabetics ref3.
In a “real world” observational study involving 15157 patients with SES acturial incidence of ST at 12 months was 0.87% ref4.
Incidence of early stent thrombosis (ST) with drug eluting stents (DES)
- This group would include
- Incidence of intra-procedural ST with DES
- Incidence of acute ST with DES
- Incidence of subacute ST in DES
The rate for this group has been in the range of 0.05 – 1.1%
Intra-procedural ST occurred in 0.7% of patients in a study of 1362 partients who received a SES. The average stent legth was 42.9±28.3 mm ref5.
A rate of 0.05 % of acute ST was observed in a study of 1911 patients who were treated with aspirin, clopidogrel and on the discretion of the treating physician, GP2b3a inhibitors ref2.
In a study of 1911 patients with DES, a subacute ST of 0.05% was observed. (2) A meta-analysis of 10 RCT involving 2602 patientes who received a DES, showed a ST rate of 0.34% by 30th day. ref7.
In the real world setting a review of the e-cypher registry involving 15157 patients with SES, rate of sub-acute ST was 0.56 % ref8.
An incidence subacute ST of 0.83 % was reported in a meta-analysis of 19 RCT ref9.
In a large observational study of more than 8000 patients with DES, the cumulative incidence of subacute stent thrombosis was 1•1% at 30 days. This accounted for 60% of total ST ref10.
Incidence of late ST in DES
- This would include
- late ST
- ST from 30 days to 365 days
- Very late ST
- ST from one year onwards
- ST beyond 3 years
- late ST
The annual incidence has been reported in the range of 0.6% to %. The reported cumulative incidence has been from % to %.
In a study of more than 8000 patients in two academic centers, the cumulative incidence of late stent thrombosis was 1•7% at 1 year, The slope of the linear portion of the cumulative incidence curve between 30 days and 3 years indicated a steady rate of 0•6% per year. (figure ) ref10.
In 1911 patients with DES, late ST rate was 0.6% with 100% follow up rateref2.
A late angiographic ST rate of 0.35% (95% confidence limits 0.17% to 0.72%).was reported in a cohort of 2006 patients with 98% of the patients being followed up. The rate from 1 month to 12 months was 0.25%. If the patients who had premature cessation of antiplatelet therapy, then the incidence of late ST was 0.2% ref11.
An incidence late ST of 0.7 % was reported in a meta-analysis of 19 RCTref9.
In a real world setting in a study involving 15157 patients with SES rate of late ST was 0.19 with an acuturial 12 month rare of 0.87%ref8.
The incidence for late ST in DES was 0.5% in a meta-analysis of 14 trials looking at 6675 patientsref12.
A meta-analysis of 10 RCT involving 2602 patients with DES revealed a late ST rate of 0.23%ref13.
In the real world setting a review of the e-cypher registry involving 15157 patients with SES, rate of late ST was 0.19 % ref8.
In a large observational study of more than 8000 patients with DES, the incidence of late stent thrombosis was 0.6%. This accounted for 40% of total number of STref10.
In an observational study involving 4666 patients, the outcomes were assessed on the basis of antiplatelet use as reported by the patients. The landmark analysis at 12 months suggested the lowest mortality with those who had a DES and who were on dual antiplatelet therapy. How ever only 35% of the original cohort was analyzed at 12 months. (see figure below)
The real incidence of thrombus formation inside a SES was shown in an elegent angioscopy study where 3 out of 17 stents showed very late thrombus formation at 21.2±2.2 months ref6.
In the real world setting and with SES an annual rate of 0.87 % was reported up to 3 yrs of follow up ref8.
In a large observational study of more than 8000 patients the cumulative incidence of very late stent thrombosis was 2•3% at 2 years, and 2•9% at 3 years. Late stent thrombosis occurred steadily at a constant rate of 0•6% per year up to 3 years after stent implantation with no evidence of diminution. 75% of patients were not followed up at three years and mortality data were taken from municipal registries. This process may have excluded some of the events. Therefore the number of events would have been higher than reported. (figure) ref10.
The incidence for very late ST for DES was 0.5% and that for SES was 0.36% in a meta-analysis of 14 trials looking at 6675 patients. The risk of ST with DES remained constant up to the end of follow up period of 4 yrs. ref12.
In a cohort of 2006 patients with DES and with a 98% follow up rate, a very late ST rate was 0.15% ref11.
In a study of serial angioscopy study of 17 patients with SES, 3 patients had visible thrombus at 21 months followupref15.
Back to main Coronary stent thrombosis page
References
- Jensen L. O. et al Stent Thrombosis, Myocardial Infarction, and Death After Drug-Eluting and Bare-Metal Stent Coronary Interventions; J Am Coll Cardiol 2007;50:463–70
- Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW, Hong MK, Kim JJ, Park SJ. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol. 2006;98:352–356
- Jacques Machecourt et al. for the EVASTENT Investigators, Risk Factors for Stent Thrombosis After Implantation of Sirolimus-Eluting Stents in Diabetic and Nondiabetic Patients The EVASTENT Matched-Cohort Registry; (J Am Coll Cardiol 2007;50:501–8
- P, Gershlick, AH, Guagliumi, G, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 2006; 113:1434.
- Chieffo A, Bonizzoni E, Orlic D, Stankovic G, Rogacka R, Airoldi F, Mikhail GW, Montorfano M, Michev I, Carlino M, Colombo A. Intraprocedural stent thrombosis during implantation of sirolimus-eluting stents. Circulation. 2004;109:2732–2736
- Masaki Awata, Jun-ichi Kotani et al; Serial Angioscopic Evidence of Incomplete Neointimal Coverage After Sirolimus-Eluting Stent Implantation. Comparison With Bare-Metal Stents Circulation published online Aug 7, 2007
- Moreno, R, Fernandez, C, Hernandez, R, et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005; 45:954.
- Urban, P, Gershlick, AH, Guagliumi, G, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 2006; 113:1434.
- Roiron, C, Sanchez, P, Bouzamondo, A, et al. Drug-eluting stents: an updated meta-analysis of randomised controlled trials. Heart 2006; 92:641
- Daemen, J, Wenaweser, P, Tsuchida, K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007; 369:667-678
- Ong, AT, McFadden, EP, Regar, E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005; 45:2088.
- Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med. 2006;119:1056 –1061.
- Moreno, R, Fernandez, C, Hernandez, R, et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005; 45:954.
- Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007;297: 159–168.
- Masaki Awata, Jun-ichi Kotani et al; Serial Angioscopic Evidence of Incomplete Neointimal Coverage After Sirolimus-Eluting Stent Implantation. Comparison With Bare-Metal Stents Circulation published online Aug 7, 2007
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
